Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ovarian Neoplasms

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 53 articles: HTML format

Single Articles

August 2023
1. KIM YN, Joung JG, Park E, Kim JW, et al
   Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
   Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34696.
   PubMed     Abstract available
   
   
   June 2023
2. FRANDSEN CLB, Svendsen PF, Nohr B, Viuff JH, et al
   Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study.
   Int J Cancer. 2023 Jun 26. doi: 10.1002/ijc.34574.
   PubMed     Abstract available
   
   
   May 2023
3. FORTNER RT, Trewin-Nybraten CB, Paulsen T, Langseth H, et al
   Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
   Int J Cancer. 2023 May 25. doi: 10.1002/ijc.34576.
   PubMed     Abstract available
   
   
   March 2023
4. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
   Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
   Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
   PubMed     Abstract available
   
   
   
5. QIN Z, Li J, Tam B, Sinha S, et al
   Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
   Int J Cancer. 2023;152:1159-1173.
   PubMed     Abstract available
   
   
   
6. SILVA R, Glennon K, Metoudi M, Moran B, et al
   Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
   Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
   PubMed     Abstract available
   
   
   February 2023
7. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
   Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
   Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
   PubMed     Abstract available
   
   
   January 2023
8. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
   Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
   Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
   PubMed     Abstract available
   
   
   December 2022
9. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
   A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
   Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
   PubMed     Abstract available
   
   
   
10. CABASAG CJ, Arnold M, Rutherford M, Ferlay J, et al
    Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34403.
    PubMed     Abstract available
    
    
    November 2022
11. HANNIBAL CG, Baandrup L, Hertzum-Larsen R, Vang R, et al
    Risk of non-ovarian cancer in a nationwide-based study of nearly 5,000 women with borderline ovarian tumors in Denmark.
    Int J Cancer. 2022 Nov 10. doi: 10.1002/ijc.34354.
    PubMed     Abstract available
    
    
    October 2022
12. GIZAW M, Parkin DM, Stoter O, Korir A, et al
    Trends in the Incidence of Ovarian Cancer in sub-Saharan Africa.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34335.
    PubMed     Abstract available
    
    
    
13. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    September 2022
14. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available
    
    
    August 2022
15. LI Y, Chen R, Yuan M, Wang D, et al
    One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34241.
    PubMed     Abstract available
    
    
    July 2022
16. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    PubMed    
    
    
    
17. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    PubMed    
    
    
    June 2022
18. HUSBY A, Wohlfahrt J, Melbye M
    Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
    Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
    PubMed     Abstract available
    
    
    
19. CAO H, Gong Y, Wang Y
    The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta-analysis and trial sequential analysis.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34179.
    PubMed     Abstract available
    
    
    
20. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
    Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
    PubMed     Abstract available
    
    
    
21. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    PubMed     Abstract available
    
    
    
22. TODISCO E, Gigli F, Ronchini C, Amato V, et al
    Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
    PubMed     Abstract available
    
    
    
23. SA JK, Kim J, Kang S, Kim SW, et al
    Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
    PubMed     Abstract available
    
    
    May 2022
24. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
    Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
    Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
    PubMed     Abstract available
    
    
    
25. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
    PubMed     Abstract available
    
    
    
26. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
    Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
    PubMed     Abstract available
    
    
    April 2022
27. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
    L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
    PubMed     Abstract available
    
    
    
28. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available
    
    
    March 2022
29. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
    Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
    Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
    PubMed     Abstract available
    
    
    February 2022
30. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
    Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
    PubMed     Abstract available
    
    
    October 2021
31. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    PubMed     Abstract available
    
    
    
32. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed     Abstract available
    
    
    September 2021
33. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    PubMed     Abstract available
    
    
    
34. IYOSHI S, Yoshihara M, Nakamura K, Sugiyama M, et al
    Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33770.
    PubMed     Abstract available
    
    
    August 2021
35. WANG T, Jake-Schoffman DE, Townsend MK, Vinci C, et al
    Early life physical activity and risk of ovarian cancer in adulthood.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33760.
    PubMed     Abstract available
    
    
    July 2021
36. COUGHLAN AY, Testa G
    Exploiting epigenetic dependencies in ovarian cancer therapy.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33727.
    PubMed     Abstract available
    
    
    June 2021
37. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    PubMed     Abstract available
    
    
    
38. PAVONE R, Pacquement H, Pasquet M, Sudour-Bonnange H, et al
    Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33710.
    PubMed     Abstract available
    
    
    May 2021
39. WANG T, Townsend MK, Eliassen AH, Terry KL, et al
    Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33676.
    PubMed     Abstract available
    
    
    April 2021
40. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    PubMed     Abstract available
    
    
    
41. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    PubMed     Abstract available
    
    
    March 2021
42. CROSBIE EJ, Flaum N, Harkness EF, Clayton RD, et al
    Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Int J Cancer. 2021;148:1155-1163.
    PubMed     Abstract available
    
    
    February 2021
43. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
    Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
    PubMed     Abstract available
    
    
    January 2021
44. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    PubMed     Abstract available
    
    
    
45. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed     Abstract available
    
    
    November 2020
46. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    PubMed     Abstract available
    
    
    
47. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    PubMed     Abstract available
    
    
    October 2020
48. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    PubMed     Abstract available
    
    
    September 2020
49. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available
    
    
    
50. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available
    
    
    
51. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed     Abstract available
    
    
    February 2020
52. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    PubMed     Abstract available
    
    
    October 2019
53. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: